Table 5. ORs between NINJ2 haplotypes and the risk of dementia.

Co-dominant model										Additive model
Haplotype	Prevalence in controls, %	0 copies		1 copy			2 copies			OR (95%CI)
		Case/Control	OR	Case/Control	OR (95%CI)	p	Case/Control	OR (95%CI)	p
AD (Global test p = 0.03)
HAP1: AGAGG	38.0	99/162	1.00	119/196	1.20 (0.82–1.74)	0.35	51/61	1.30 (0.79–2.14)	0.30	1.15 (0.91–1.46)
HAP2: CAGGA	23.8	169/241	1.00	99/161	0.98 (0.69–1.41)	0.93	5/19	0.32 (0.11–0.94)	0.04	0.83 (0.61–1.12)
HAP3: CGGGG	16.8	179/289	1.00	81/114	1.17 (0.80–1.71)	0.42	7/14	0.67 (0.24–1.86)	0.44	1.03 (0.75–1.42)
HAP4: CAAGG	10.0	221/335	1.00	43/70	0.83 (0.53–1.31)	0.43	2/6	0.21 (0.04–1.18)	0.08	0.72 (0.48–1.08)
HAP5: CGAAG	8.9	225/348	1.00	45/71	1.08 (0.69–1.70)	0.74	4/2	2.99 (0.49–18.21)	0.23	1.19 (0.79–1.78)
VaD (Global test p = 0.70)
HAP1: AGGGG	38.0	45/162	1.00	54/198	1.19 (0.73–1.95)	0.51	15/61	0.91 (0.45–1.87)	0.82	1.01 (0.73–1.40)
HAP2: CAAGA	23.8	64/240	1.00	45/162	1.04 (0.65–1.67)	0.84	6/19	1.31 (0.46–3.70)	0.59	1.09 (0.74–1.59)
HAP3: CGAGG	16.8	81/291	1.00	32/113	1.17 (0.71–1.95)	0.60	1/14	0.21 (0.03–1.76)	0.15	0.92 (0.60–1.42)
HAP4: CAGGG	10.0	93/337	1.00	17/70	0.69 (0.37–1.32)	0.25	3/6	0.78 (0.17–3.69)	0.77	0.76 (0.46–1.27)
HAP5: CGGAG	8.9	86/348	1.00	28/71	1.42 (0.82–2.45)	0.20	0/2	NA	NA	1.27 (0.75–2.15)
Cumulative frequency	97.5

Abbreviation: NA, not applicable.

All models were adjusted for age and gender.